Company Releases - Pharmaceutical Technology

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Advertise with us

Clinical Trials

Roche makes a cautious investment in Ionis’ dAMD drug

ESMO 2018: previewing high-impact, late-breaking abstracts

AbbVie/J&J’s Imbruvica expected to post encouraging PFS rates in CLL

Cold Chain

Brexit backlash: EU cuts UK’s MHRA out of drug approval process

Roche’s Rituxan biosimilar woes are just beginning

Blockbuster asthma drug Xolair gains breakthrough status for food allergies

Diseases

Roche makes a cautious investment in Ionis’ dAMD drug

ESMO 2018: previewing high-impact, late-breaking abstracts

AbbVie/J&J’s Imbruvica expected to post encouraging PFS rates in CLL

Drug Development

Roche makes a cautious investment in Ionis’ dAMD drug

ESMO 2018: previewing high-impact, late-breaking abstracts

Could Brazilian-style incentives boost the US biosimilar market?

Manufacturing

Roche makes a cautious investment in Ionis’ dAMD drug

ESMO 2018: previewing high-impact, late-breaking abstracts

Could Brazilian-style incentives boost the US biosimilar market?

Market Data

Roche makes a cautious investment in Ionis’ dAMD drug

ESMO 2018: previewing high-impact, late-breaking abstracts

Could Brazilian-style incentives boost the US biosimilar market?

Obsessions

NHS Genomic Medicine Service: the UK seeks to build a global genomic hub

Patient death following CAR-T therapy highlights serious manufacturing issues

Pharma Technology Focus – Special Issue